 | Up a level |
Bernhard, Jürg; Dietrich, Daniel; Glimelius, Bengt; Bodoky, György; Scheithauer, Werner; Herrmann, Richard (2014). Clinical benefit response in pancreatic cancer trials revisited. Oncology research and treatment, 37(1-2), pp. 42-48. Karger 10.1159/000357965
Koeberle, Dieter; Betticher, Daniel; Von Moos, Roger; Dietrich, Daniel; Brauchli, Peter; Baertschi, Daniela; Matter-Walstra, Klazien; Winterhalder, Ralph; Borner, Markus; Anchisi, Sandro; Moosmann, Peter; Kollár, Attila; Saletti, Piercarlo; Roth, Arnaud; Frueh, Martin; Kueng, Marc; Popescu, Razvan; Schacher, Sabina; Hess, Viviane and Herrmann, Richard (2013). O-0028 Bevacizumab Continuation Versus No Continuation After First-Line Chemo-Bevacizumab Therapy in Patients with Metastatic Colorectal Cancer: a Phase 3 Non-Inferiority Trial. Annals of oncology, 24(Suppl 4), iv22-iv22. Oxford University Press 10.1093/annonc/mdt201.28
Schuller, Jan C.; Brauchli, Peter; Dietrich, Daniel; Herrmann, Richard; Klingbiel, Dirk; Lerch, Stefanie; Mayer, Michael; Simcock, Mathew; Hsu Schmitz, Shu-Fang (2009). Should phase II cancer screening trials include a control arm? 30th Annual Conference of the International Society for Clinical Biostatistics, August 23-27, 2009, Prague.
Koeberle, Dieter; Saletti, Piercarlo; Borner, Markus; Gerber, Daniela; Dietrich, Daniel; Caspar, Clemens B; Mingrone, Walter; Beretta, Kurt; Strasser, Florian; Ruhstaller, Thomas; Mora, Oreste; Herrmann, Richard (2008). Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research. Journal of clinical oncology, 26(22), pp. 3702-8. Alexandria, Va.: American Society of Clinical Oncology 10.1200/JCO.2008.16.5704
Bernhard, Jürg; Dietrich, Daniel; Scheithauer, Werner; Gerber, Daniela; Bodoky, György; Ruhstaller, Thomas; Glimelius, Bengt; Bajetta, Emilio; Schüller, Johannes; Saletti, Piercarlo; Bauer, Jean; Figer, Arie; Pestalozzi, Bernhard C; Köhne, Claus-Henning; Mingrone, Walter; Stemmer, Salomon M; Tàmas, Karin; Kornek, Gabriela V; Koeberle, Dieter; Herrmann, Richard; ... (2008). Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001. Journal of clinical oncology, 26(22), pp. 3695-701. Alexandria, Va.: American Society of Clinical Oncology 10.1200/JCO.2007.15.6240
Bernhard, Jürg; Lowy, Adam; Mathys, Natascha; Herrmann, Richard; Hürny, Christoph (2004). Health related quality of life: a changing construct? Quality of life research, 13(7), pp. 1187-97. Dordrecht: Springer 10.1023/B:QURE.0000037485.59681.7d
Sabbioni, Marzio E E; Bernhard, Jürg; Siegrist, Hans-Peter; Schmitz, Shu-Fang Hsu; Gertsch, Monica Castiglione; Thürlimann, Beat; Bonnefoi, Hervé; Perey, Lucien; Herrmann, Richard; Goldhirsch, Aron; Hürny, Christoph; Swiss Group for Clinical Cancer Research, (SAKK) (2004). Does subjective burden of early breast cancer and its treatment affect immune measures during adjuvant therapy? Breast cancer research and treatment, 87(1), pp. 75-86. Dordrecht: Springer 10.1023/B:BREA.0000041584.53863.a7
